We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2012 by Haihua Yang, Taizhou Hospital.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01534585
First Posted: February 16, 2012
Last Update Posted: February 20, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Haihua Yang, Taizhou Hospital
February 13, 2012
February 16, 2012
February 20, 2012
February 2012
February 2013   (Final data collection date for primary outcome measure)
  • Phase I: the maximum tolerated dose of Icotinib in combination with IMRT for NPC [ Time Frame: 30 days ]
  • Phase II: 2 years locoregional control rate [ Time Frame: Two years ]
  • Phase I: the maximum tolerated dose of Icotinib in combination with IMRT for NPC [ Time Frame: 30 days ]
  • Phase II: the rate of locoregional control at two year [ Time Frame: Two years ]
Complete list of historical versions of study NCT01534585 on ClinicalTrials.gov Archive Site
  • The overall response rate (complete and partial response) [ Time Frame: 1 month following treatment and then every 3 months ]
  • The acute and late toxicity profile associated with the study regimen [ Time Frame: 1 month following treatment and then every 3 months ]
  • The duration of control of locoregional disease [ Time Frame: 1 month following treatment and then every 3 months ]
  • Overall survival, disease-free survival, and distant relapse rates [ Time Frame: At time of locoregional disease progression ]
  • EGFR status in tissue and blood before treatment [ Time Frame: 2 week of pretreatment ]
  • The overall response rate (complete and partial response) [ Time Frame: 1 month following treatment and then every 3 months ]
  • The acute and late toxicity profile associated with the study regimen [ Time Frame: 1 month following treatment and then every 3 months ]
  • The duration of control of locoregional disease [ Time Frame: 1 month following treatment and then every 3 months ]
  • Overall survival, disease-free survival, and distant relapse rates [ Time Frame: At time of locoregional disease progression ]
  • EGFR status about tissue and blood before treatment [ Time Frame: 2 week of pretreatment ]
Not Provided
Not Provided
 
Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma
Phase Ⅰ/Ⅱ Study of Icotinib Hydrochloride Combined With Intensity-modulated Radiotherapy in Nasopharyngeal Cancer
Nasopharyngeal carcinoma (NPC) is a prevalent disease in southeast of China. Radiation therapy with or without chemotherapy is a standard therapy for nasopharyngeal cancer. Cytotoxic chemotherapy plays an important role in the curative treatment of advanced NPC. However, concurrent chemoradiotherapy increased significantly local and systemic toxic effects, which may preclude many patients from proceeding with combined therapy. The epidermal growth factor receptor(EGFR) gene is amplified in 40% and EGFR protein is overexpressed in over 80% of NPC. EGFR overexpression is also associated with shorter survival following chemoradiotherapy in locoregionally advanced NPC. And some basic researches have proved that EGFR tyrosine kinase inhibitors(TKIs) could increase the radiosensitivity and reduce the epithelial-mesenchymal transition (EMT) in NPC cell line. Moreover, distant metastases has been the major cause of treatment failure in NPC. Icotinib hydrochloride is a novel oral EGFR TKIs with low mammalian toxicity(made in China). But base on toxic effects of Icotinib, it may increase toxic effects about skin and mucosa in combination therapy with Icotinib and Intensity-modulated Radiotherapy (IMRT). The prospective study will assess the tolerability and efficacy of Icotinib combined with IMRT in patients with NPC. This regimen is of great interest and it has potential to alleviate the adverse effects, improve patient compliance and better therapeutic ratio.
Not Provided
Interventional
Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Nasopharyngeal Carcinoma
  • Drug: Icotinib

    Oral Icotinib begins on day 1 and continues until completion of radiotherapy. Phase I:The initial plan is to accrue 6 patients to each dose level (125mg, qd and bid and tid) in each cohort. If one or none of six patients have dose limiting toxicity (DLT), then escalation will proceed. If DLT occurs in two or more patients at a dose level, then escalation will be stopped. The dose level below that at which two of six patients experience a DLT is defined as the maximum-tolerated dose. A minimum of 4 weeks of observation is required after completion of radiation within each Icotinib dose level before accrual to the next level.

    Phase II:According to the maximum tolerated dose, 50 patients will been recruited.

    Other Name: Conmana
  • Radiation: intensity-modulated radiotherapy
    The nasopharyngeal regions and upper neck with IMRT plans will be generated and approved for each patient, whereas the low-neck and supraclavicular regions will be used with a conventional anterior field. A total of 70-76Gy at 2.12-2.3Gy/fraction/d will be given to the GTVnx, the GTVnd will receive 66-70Gy at 2.0-2.12Gy/fraction/d, the CTV1 will receive 60-66Gy at 1.8-2.0Gy/fraction/d, and the CTV2 received 56-60Gy at 1.7-1.8Gy/fraction/d with IMRT. The low-neck and supraclavicular regions will receive 50-60Gy at 2.0Gy/fraction/d with conventional radiotherapy. Target prescription dose and critical structures limit dose are planned according to the RTOG0225 trial.
    Other Name: IMRT
  • Drug: Paclitaxel and Cisplatin
    AC that consisted of two cycles of paclitaxel 135 mg/m2 on day 1 plus cisplatin 30 mg/m2 on days 1-3 will start 4 weeks after the end of CRT.
  • Other: Quality of life
    The EORTC QLQ-C30 and H&N35 of the Chinese version, which is obtained from the Quality of Life Unit, EORTC Data Center in Brussels, Belgium, is available and easily completed by our patients are chosen for this study. Patients will complete the questionnaire before treatment and after treatment and one month after treatment and three months after treatment and one year after treatment.
    Other Name: QoL
  • Genetic: Epidermal growth factor receptor status
    EGFR expression and mutation before treatment.
    Other Name: EGFR
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
60
February 2015
February 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients with histological proof of squamous carcinoma of the nasopharynx.
  2. Patients must have ECOG Performance Status of 0-1.
  3. Patients should have adequate bone marrow function defined as an absolute peripheral granulocyte count (AGC) of >/= 1500 cells/mm3, platelet count of >/= 100,000 cells/mm3; adequate hepatic function with bilirubin </= 1.5mg/dl, AST and ALT </= 2x the upper limit of normal; serum creatinine </= 1.5mg/dl, creatinine clearance >/= 50 ml/min and INR 0.8 - 1.2.
  4. Patients must sign a study specific informed consent form prior to study entry.

Exclusion Criteria:

  1. Evidence of metastases by clinical or radiographic examinations.
  2. History of malignancy other than non-melanoma skin cancer.
  3. Prior chemotherapy or anticancer biologic therapy for any type of cancer, or prior radiotherapy to the head and neck region except for radioactive iodine therapy.
  4. Patients with uncontrolled intercurrent disease.
  5. Patients with currently active malignancy.
  6. Pregnant or lactating women Female patients of childbearing potential who are unwilling to practice adequate contraception during study treatment and for two months after the last administration of study drug.
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
China
 
 
NCT01534585
YHH-201201
Yes
Not Provided
Not Provided
Haihua Yang, Taizhou Hospital
Taizhou Hospital
Not Provided
Study Director: Haihua Yang, MD. Department of Radiation Oncology, Taizhou Hospital, Wenzhou Medical College.
Study Chair: Wei Hu, MD. Department of Radiation Oncology, Taizhou Hospital, Wenzhou Medical College.
Principal Investigator: Wei Wang, BS Department of Radiation Oncology, Taizhou Hospital, Wenzhou Medical College.
Principal Investigator: Chao Zhou, MD. Department of Radiation Oncology, Taizhou Hospital, Wenzhou Medical College.
Taizhou Hospital
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP